

## CREVALUABLE COMPANY, CREATIVE COMPANY, **BEAUTIFUL COMPANY**



www.ckdpharm.com/en/home

## **CHONG KUN DANG**

Chong Kun Dang Pharmaceutical Corp. (CKD) was established in 1941 with a goal of supplying the best quality medicines. In 1968, CKD received US FDA approval for Chloramphenicol. Remarkably, CKD is one of the first Korean pharmaceutical companies to establish Research Center in early 1970's to accelerate the development of novel technologies and therapeutics. As a result, CKD has successfully launched two novel therapeutics, Camtobell for anti-cancer and Duvie for type 2 diabetes, and world's first NESP biosimilar, Nesbell.

## **Main Products**








Category	Brand Name	Ingredients	Note
Oncology	Camtobell Inj	Belotecan	New Drugs
Type 2 diabetes	Duvie Tab	Lobeglitazone	New Drugs
Antihypertensive drugs	Dilatrend Tab	Carvedilol	
Immunology	Tarcrobell Cap	Tarcrolilmus	
Antihyperlipidemic agent	Lipilou Tab	Atrovastain	
Nootropic Agents	CKD Gliatilin Soft Cap	Choline Alfoscerate	

## **R&D** Pipeline

**New Chemical Drugs/Biologics** 



Rare Disease (HDAC6 inhibitor)

∞ Biologics / \* In-licensed product



CEO YOUNG JOO KIM

Location

8 Chungjeong-ro, Seodaemungu, Seoul, Korea

Specialty

- 1. Anticancer New Drugs
- 2. Antidiabetic New Drugs
- 3. Autoimmune Diseases

Tel / Fax / E-mail

- T. 82-2-2194-0300
- F. 82-2-2194-0369
- E. youngjookim@ ckdpharm.com